Supplementary Materialsoncotarget-10-6845-s001. immunocompetent sponsor, making this model useful for studying mechanisms of bone metastasis and tumor immune response. = 4 third passage B6CaP tumors grown in parallel) indicated abundant infiltration of CD3+ T cells, CD19+ B cells, and CD49b+ NK cells (Figure 2D, Supplementary Derazantinib (ARQ-087) Figure 1). Since immunotherapy regimens most commonly employ monoclonal antibodies targeting regulatory checkpoints [13], we determined the expression levels of four immune checkpoints (CTLA4, LAG3, PD1, and TIM3) on tumor infiltrating T cells, and PD-L1 expression on B6CaP tumor cells. Infiltrating T cells, especially CD8+ T cells, often expressed PD-1 and TIM3, and tumor cells were frequently positive for PD-L1 (Figure 2EC2F, Supplementary Figure 2). Open in a separate window Figure 2 Immune profile of B6CaP.(A, B) Immunohistochemistry for IBA-1 (A), CD11b (B), and F4/80 (C) indicate high levels of infiltration by macrophage/myeloid cell types. (D) Tumor infiltrating lymphocyte (TIL) populations characterized by flow cytometry of dissociated allografts (mean +/C standard deviation). (E) Immune checkpoint expression of tumor infiltrating T cells. (F) PD-L1 expression of dissociated tumor cells. Growth and metastasis profile of B6CaP cells In order to determine the growth and metastasis profile of B6CaP cells, we digested freshly resected allografts into single cell suspensions and implanted them into immunocompetent C57BL/6J mice by multiple routes (Table 1). When implanted as flank subcutaneous allografts, tumors formed in 48/50 (96%) mice. The mice were euthanized for tissue collection when the tumors reached 1.5 cm diameter. At this timepoint, 11/48 (23%) mice had metastatic lesions in the lungs. Due to a rapid growth of the subcutaneous tumors, the survival of injected mice was limited to approximately 6 weeks. In order to allow a Rtn4r longer time period for metastases to develop, established subcutaneous xenografts were surgically resected when the tumors were 1 cm in diameter and the mice were followed for an additional 8- or 16-weeks post resection. At these later time points, metastases were identified in 21% and 67% of mice, respectively. Orthotopic injection of tumor cells into the anterior prostate also showed metastatic potential, with 60% of pets displaying metastasis to lungs (Desk 1), and stomach lymph node metastases within 4/10 (40%) of mice. Intravenous inoculation of B6Cover cells led to development of metastatic foci in multiple sites, including bone tissue, but growth of several lung metastases led to early euthanasia frequently. Intravenous injection of just one 1 10^5 B6Cover cells led to development of lung tumors in 14/21 mice (67%). In comparison, injection of just one 1 10^5 cells through the Myc-CaP cell range into syngeneic FVB/N mice led to development of lung metastases in considerably fewer mice (3/11, 27%, = 0.034). Desk 1 Metastasis profile of B6Cover allografts Delivery Regional Development Lung Mets Bone tissue Mets Subcutaneous 48/50 (96%)11/48 (23%)0/48 (0%) Subcutaneous (organoid) 4/4 (100%)2/4 (50%)0/4 (0%) SQ Resected 8 wks N/A4/19 (21%)0/19 (0%) SQ Resected 16 wks N/A8/12 (67%)0/12 (0%) Intravenous N/A14/21 (67%)9/21 (43%) Intracardiac 29/57 (51%)26/57 (46%)33/57 (58%) Intracardiac (organoid) 0/4 (0%)2/4 (50%)2/4 (50%) Orthotopic 10/10 (100%)6/10 (60%)0/10 (0%) MycCaP Intravenous N/A3/11 (27%)0/11 (0%) Open up in another windowpane = 57)44 (77%)33 (58%)30 (53%)10 (18%)15 (26%)14 (25%)7 (12%)Additional sites Lung (26), Lymph Node Derazantinib (ARQ-087) (9), Attention (7), Epididymis (2), Mind (2), Spleen (2) Open up in another window B6Cover tumors had been implanted by subcutaneous, intravenous, intracardiac, or orthotopic routes. Some subcutaneous tumors had been resected if they reached 1 cm size. For assessment, MycCaP mice had been injected into syngeneic mice by intravenous path. Columns represent amount of mice with regional development at shot site, lung metastases, or bone tissue metastases at necropsy. For mice with intracardiac B6Cover injections, lower -panel indicates extra sites of metastases. Any Met identifies any faraway metastasis, or development at any site apart from center/pericardium. Intravascular inoculation of tumor cells, either intravenous injection via Derazantinib (ARQ-087) tail vein or intracardiac injection, generated widespread metastases with frequent bone metastases. However,.